Elan and Biogen Idec to present TYSABRI study data at ACG meeting

NewsGuard 100/100 Score

Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDQ: BIIB) today announced multiple presentations at the American College of Gastroenterology (ACG) Annual Scientific Meeting, taking place October 23-28 in San Diego.

The posters and presentations during ACG will highlight TYSABRI® (natalizumab) data in treating Crohn’s Disease. During a plenary session on inflammatory bowel disease (IBD), an oral presentation will focus on a retrospective subset analysis of two registrational Phase 3 trials (ENACT-2 [Evaluation of Natalizumab as Continuous Therapy] and ENCORE [Efficacy of Natalizumab in Crohn’s Disease Response and Remission]) and one open-label study (ENABLE). Corey A. Siegel, MD, director of the Inflammatory Bowel Disease (IBD) Center at Dartmouth-Hitchcock Medical Center will give the presentation. In addition, representatives from Elan and investigators will present four posters that analyze patient reported outcomes from the TOUCH study, and one poster reporting the utilization and safety results from the TOUCH™ prescribing and surveillance program.

SOURCE Elan Corporation, plc


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Charting the future of IBD treatment: From immune modulators to microRNA therapies